Compare ARK Genomic Revolution ETF (ARKG) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Marsh & McLennan Companies, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.28, while Marsh & McLennan Companies, Inc. trades at $180.82 (market cap $85.91B). The key difference: Marsh & McLennan Companies, Inc. pays a 2.22% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Marsh & McLennan Companies, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | MRSH | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $213.57 |
52-Week Low | $23.09 | $157.32 |
Market Cap | — | $85.91B |
Enterprise Value | — | $106.75B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Marsh (MRSH) trades at $178.31, down 0.39% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.29 exceeding expectations, and recently raised its quarterly dividend by 10% to $0.99 per share. Revenue growth has been steady, reaching $26.98 billion in 2025, supported by a robust net income margin of 14.26%.
The outlook remains positive given consistent earnings outperformance and shareholder returns, though valuation multiples like a P/E of 22.29 and P/B of 5.9 suggest a premium. Risks include easing pricing tailwinds in insurance and rising costs. Analysts are predominantly neutral with a consensus price target of $199.44, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
